New lithium pill aims to improve bipolar treatment
Disease control
Recruiting now
This study compares a new form of lithium (AL001) to the standard lithium carbonate in 20 adults with bipolar I disorder. Participants will take each drug for 14 days and undergo MRIs and blood tests to see how the drugs behave in the brain and body. The goal is to find out if AL…
Phase: PHASE1, PHASE2 • Sponsor: Alzamend Neuro, Inc. • Aim: Disease control
Last updated May 14, 2026 12:03 UTC